Compare Sun Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DIVIS LABORATORIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DIVIS LABORATORIES SUN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 30.2 66.4 45.5% View Chart
P/BV x 4.0 14.6 27.2% View Chart
Dividend Yield % 1.0 0.4 249.5%  

Financials

 SUN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SUN PHARMA
Mar-21
DIVIS LABORATORIES
Mar-21
SUN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6543,913 16.7%   
Low Rs3391,824 18.6%   
Sales per share (Unadj.) Rs139.6262.5 53.2%  
Earnings per share (Unadj.) Rs9.574.7 12.7%  
Cash flow per share (Unadj.) Rs18.284.4 21.6%  
Dividends per share (Unadj.) Rs7.5020.00 37.5%  
Avg Dividend yield %1.50.7 216.8%  
Book value per share (Unadj.) Rs193.6350.1 55.3%  
Shares outstanding (eoy) m2,399.34265.47 903.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x3.610.9 32.5%   
Avg P/E ratio x52.138.4 135.8%  
P/CF ratio (eoy) x27.334.0 80.2%  
Price / Book Value ratio x2.68.2 31.3%  
Dividend payout %78.826.8 294.4%   
Avg Mkt Cap Rs m1,190,430761,517 156.3%   
No. of employees `000NANA-   
Total wages/salary Rs m68,6228,258 831.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m334,98169,694 480.6%  
Other income Rs m8,592626 1,373.4%   
Total revenues Rs m343,57370,320 488.6%   
Gross profit Rs m41,61628,612 145.5%  
Depreciation Rs m20,8002,556 813.8%   
Interest Rs m1,41421 6,734.8%   
Profit before tax Rs m27,99426,660 105.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,1476,818 75.5%   
Profit after tax Rs m22,84719,843 115.1%  
Gross profit margin %12.441.1 30.3%  
Effective tax rate %18.425.6 71.9%   
Net profit margin %6.828.5 24.0%  
BALANCE SHEET DATA
Current assets Rs m304,42167,906 448.3%   
Current liabilities Rs m161,45617,284 934.2%   
Net working cap to sales %42.772.6 58.8%  
Current ratio x1.93.9 48.0%  
Inventory Days Days14910 1,565.3%  
Debtors Days Days99878 11.2%  
Net fixed assets Rs m336,68245,963 732.5%   
Share capital Rs m2,399531 451.9%   
"Free" reserves Rs m462,22992,415 500.2%   
Net worth Rs m464,62892,946 499.9%   
Long term debt Rs m8,9810-   
Total assets Rs m641,103113,869 563.0%  
Interest coverage x20.81,270.5 1.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 85.4%   
Return on assets %3.817.4 21.7%  
Return on equity %4.921.3 23.0%  
Return on capital %6.228.7 21.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,4930-   
Fx outflow Rs m30,3340-   
Net fx Rs m54,1590-   
CASH FLOW
From Operations Rs m61,70419,469 316.9%  
From Investments Rs m5,362751 713.7%  
From Financial Activity Rs m-59,805-349 17,141.0%  
Net Cashflow Rs m5,96419,872 30.0%  

Share Holding

Indian Promoters % 54.7 52.0 105.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 32.8 37.2 88.3%  
FIIs % 12.7 20.6 61.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 45.3 48.1 94.3%  
Shareholders   653,359 193,883 337.0%  
Pledged promoter(s) holding % 6.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   CHANDRA BHAGAT PHARMA  BAFNA PHARMA  ALCHEMIST LIMITED  PROCTER & GAMBLE HEALTH  AUROBINDO PHARMA  



Today's Market

Sensex Slumps 700 Points from Day's High to End Lower; Tata Steel & SBI Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

DIVIS LABORATORIES 2020-21 Annual Report Analysis (Annual Result Update)

Aug 12, 2021 | Updated on Aug 12, 2021

Here's an analysis of the annual report of DIVIS LABORATORIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY22); Net Profit Up 13.2% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, DIVIS LABORATORIES has posted a net profit of Rs 6 bn (up 13.2% YoY). Sales on the other hand came in at Rs 20 bn (up 13.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY21); Net Profit Up 29.3% (Quarterly Result Update)

Jun 28, 2021 | Updated on Jun 28, 2021

For the quarter ended March 2021, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 29.3% YoY). Sales on the other hand came in at Rs 18 bn (up 28.7% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider(Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore(Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market(Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race(Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

Revenge Travel is Here. 9 Stocks Likely to Benefit(Views On News)

Sep 4, 2021

The term 'revenge travel' refers to the desire of going on a vacation after an extended period of lockdown.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 17, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS